Alloksys Life Sciences

Executive Summary

Alloksys Life Sciences is a Dutch biopharmaceutical company pioneering alkaline phosphatase-based therapies for critical care patients. Founded in 2008 and headquartered in Wageningen, the company is currently in Phase 2 clinical development. Its lead candidate, a recombinant alkaline phosphatase, aims to mitigate inflammatory and organ damage in conditions such as sepsis and acute kidney injury by dephosphorylating harmful extracellular ATP and LPS. This mechanism targets unmet needs in the ICU, where no targeted therapies exist for these life-threatening complications. The company’s approach leverages decades of research on the protective role of alkaline phosphatase in inflammation. With a strong intellectual property portfolio and support from European innovation grants, Alloksys is positioned to address a large global market. However, the company remains private and has not disclosed total funding or valuation, indicating a need for future capital raising or partnership. If successful, its therapy could transform critical care outcomes, but it faces typical clinical and regulatory risks associated with Phase 2 development.

Upcoming Catalysts (preview)

• Q1 2027Phase 2a top-line data for AP in sepsis-associated acute kidney injury45% success
• H2 2026Announcement of Series B or strategic partnership60% success
• H2 2026FDA or EMA orphan drug designation for lead indication70% success